The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Exosomal long noncoding RNA CRNDE-h as a novel serum-based biomarker for diagnosis and prognosis of colorectal cancer
Open accessAbstract
// Tong Liu 1, * , Xin Zhang 1, * , Shanyu Gao 2 , Fangmiao Jing 3 , Yongmei Yang 1 , Lutao Du 1 , Guixi Zheng 1 , Peilong Li 1 , Chen Li 1 , Chuanxin Wang 1 1 Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, People’s Republic of China 2 Department of Anorectal Surgery, Shandong Provincial Traditional Chinese Medical Hospital, Jinan, People’s Republic of China 3 Oncology Center, Qilu Hospital, Shandong University, Jinan, People’s Republic of China * These authors have contributed equally to this work Correspondence to: Chuanxin Wang, email: cxwang@sdu.edu.cn Keywords: exosome, long noncoding RNA, CRNDE-h, colorectal cancer, biomarker Received: August 02, 2016 Accepted: October 27, 2016 Published: November 19, 2016 ABSTRACT Cancer-secreted long non-coding RNAs (lncRNAs) are emerging mediators of cancer-host cross talk. The aim of our study was to illustrate the clinical significance of the lncRNA CRNDE-h in exosomes purified from the serum of patients with colorectal cancer (CRC). The study was divided into four parts: (1) The exosome isolated methods and lncRNA detected methods which accurately and reproducibly measure CRC-related exosomal CRNDE-h in serum were optimized in preliminary pilot stage; (2) The stability of exosomal CRNDE-h was evaluated systematically; (3) The origin of exosomal CRNDE-h was explorated in vitro and in vivo ; (4) The diagnostic and prognostic value of exosomal CRNDE-h for CRC were validated in 468 patients. In pilot study, our results indicated that exosomal CRNDE-h was detectable and stable in serum of CRC patients, and derived from tumor cells. Then, the increased expression of exosomal CRNDE-h was successfully validated in 148 CRC patients when compared with colorectal benign disease patients and healthy donors. Exosomal CRNDE-h level significantly correlated with CRC regional lymph node metastasis ( P = 0.019) and distant metastasis ( P = 0.003). Moreover, at the cut-off value of 0.020 exosomal CRNDE-h level of serum, the area under ROC curve distinguishing CRC from colorectal benign disease patients and healthy donors was 0.892, with 70.3% sensitivity and 94.4% specificity, which was superior to carcinoembryogenic antigen. In addition, high exosomal CRNDE-h level has a lower overall survival rates than that for low groups (34.6% vs. 68.2%, P < 0.001). In conclusion, detection of lncRNA CRNDE-h in exosome shed a light on utilizing exosomal CRNDE-h as a noninvasive serum-based tumor marker for diagnosis and prognosis of CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., & Speleman, F. (2002) · Genome Biology · doi:10.1186/gb-2002-3-7-research0034 · Cited by 20,038
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
Khalil, A. M., Guttman, M., Huarte, M., Garber, M., Raj, A., Rivea Morales, D., Thomas, K., Presser, A., Bernstein, B. E., van Oudenaarden, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904715106 · Cited by 2,872
Edwards, B. K., Noone, A., Mariotto, A. B., Simard, E. P., Boscoe, F. P., Henley, S. J., Jemal, A., Cho, H., Anderson, R. N., Kohler, B. A., et al. (2014) · Cancer · doi:10.1002/cncr.28509 · Cited by 1,210
Enderle, D., Spiel, A., Coticchia, C. M., Berghoff, E., Mueller, R., Schlumpberger, M., Sprenger-Haussels, M., Shaffer, J. M., Lader, E., Skog, J., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0136133 · Cited by 396
Takahashi, K., Yan, I. K., Kogure, T., Haga, H., & Patel, T. (2014) · FEBS Open Bio · doi:10.1016/j.fob.2014.04.007 · Cited by 376
Zhou, X., Yin, C., Dang, Y., Ye, F., & Zhang, G. (2015) · Scientific Reports · doi:10.1038/srep11516 · Cited by 334
Tong, Y.-S., Wang, X.-W., Zhou, X.-L., Liu, Z.-H., Yang, T.-X., Shi, W.-H., Xie, H.-W., Lv, J., Wu, Q.-Q., & Cao, X.-F. (2015) · Molecular Cancer · doi:10.1186/1476-4598-14-3 · Cited by 317
Ren, S., Wang, F., Shen, J., Sun, Y., Xu, W., Lu, J., Wei, M., Xu, C., Wu, C., Zhang, Z., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.04.026 · Cited by 312
Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers
Takahashi, Y., Sawada, G., Kurashige, J., Uchi, R., Matsumura, T., Ueo, H., Takano, Y., Eguchi, H., Sudo, T., Sugimachi, K., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.698 · Cited by 287
Nissan, A., Stojadinovic, A., Mitrani‐Rosenbaum, S., Halle, D., Grinbaum, R., Roistacher, M., Bochem, A., Dayanc, B. E., Ritter, G., Gomceli, I., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.26170 · Cited by 282
CRNDE, a long-noncoding RNA, promotes glioma cell growth and invasion through mTOR signaling
Wang, Y., Wang, Y., Li, J., Zhang, Y., Yin, H., & Han, B. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.03.027 · Cited by 275
Berrondo, C., Flax, J., Kucherov, V., Siebert, A., Osinski, T., Rosenberg, A., Fucile, C., Richheimer, S., & Beckham, C. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0147236 · Cited by 266
High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer.
Zheng, H.-T., Shi, D.-B., Wang, Y., Li, X.-X., Xu, Y., Tripathi, P., Gu, W.-L., Cai, G.-X., & Cai, S.-J. (2014) · PubMed · Cited by 258
Takahashi, K., Yan, I. K., Wood, J., Haga, H., & Patel, T. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0636 · Cited by 258
Davoren, P. A., McNeill, R. E., Lowery, A. J., Kerin, M. J., & Miller, N. (2008) · BMC Molecular Biology · doi:10.1186/1471-2199-9-76 · Cited by 257
Graham, L. D., Pedersen, S. K., Brown, G. S., Ho, T., Kassir, Z., Moynihan, A. T., Vizgoft, E. K., Dunne, R., Pimlott, L., Young, G. P., et al. (2011) · Genes & Cancer · doi:10.1177/1947601911431081 · Cited by 256
Long non-coding RNAs in cancer progression
Tano, K., & Akimitsu, N. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00219 · Cited by 251
Le Dieu, R., Taussig, D. C., Ramsay, A. G., Mitter, R., Miraki-Moud, F., Fatah, R., Lee, A. M., Lister, T. A., & Gribben, J. G. (2009) · Blood · doi:10.1182/blood-2009-02-206946 · Cited by 243
CRNDE: A Long Non-Coding RNA Involved in CanceR, Neurobiology, and DEvelopment
Ellis, B. C., Molloy, P. L., & Graham, L. D. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00270 · Cited by 228
Ellis, B. C., Graham, L. D., & Molloy, P. L. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.10.016 · Cited by 210
Exosomal lncRNA-p21 levels may help to distinguish prostate cancer from benign disease
Işın, M., Uysaler, E., Özgür, E., KöseoÄŸlu, H., Åžanlı, Ã., Yücel, Ã. B., Gezer, U., & Dalay, N. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00168 · Cited by 204
Perspectives of Long Non-Coding RNAs in Cancer Diagnostics
Reis, E. M., & Verjovski-Almeida, S. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00032 · Cited by 164
Wang, C., Liu, T., Zhang, X., Yang, Y., & Du, L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s98268 · Cited by 90
Self-citationKhalyfa, A., Almendros, I., Gileles‐Hillel, A., Akbarpour, M., Trzépizur, W., Mokhlesi, B., Huang, L., Andrade, J., Farré, R., & Gozal, D. (2016) · Oncotarget · doi:10.18632/oncotarget.10578 · Cited by 71
Laurent, L. C., Abdel‐Mageed, A. B., Adelson, P. D., Arango, J. I., Balaj, L., Breakefield, X. O., Carlson, E. W. J., Carter, B. S., Majem, B., Chen, C. C., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.26533 · Cited by 70
Zhang, X., Yang, X., Zhang, Y., Liu, X., Zheng, G., Yang, Y., Wang, L., Du, L., & Wang, C. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1761 · Cited by 34
Self-citation
Cited by
Exosomes: biogenesis, biologic function and clinical potential
Zhang, Y., Liu, Y., Liu, H., & Tang, W. H. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0282-2 · Cited by 2,119
Extracellular vesicles in cancer — implications for future improvements in cancer care
Xu, R., Rai, A., Chen, M., Suwakulsiri, W., Greening, D. W., & Simpson, R. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0036-9 · Cited by 1,445
Extracellular vesicles as tools and targets in therapy for diseases
Kumar, M. A., Baba, S. K., Sadida, H. Q., Marzooqi, S. A., Jerobin, J., Altemani, F. H., Algehainy, N., Alanazi, M. A., Abou-Samra, A.-B., Kumar, R., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01735-1 · Cited by 1,343
Innovative approaches for cancer treatment: current perspectives and new challenges
Pucci, C., Martinelli, C., & Ciofani, G. (2019) · ecancermedicalscience · doi:10.3332/ecancer.2019.961 · Cited by 814
Clinical utility of circulating non-coding RNAs — an update
Anfossi, S., Babayan, A., Pantel, K., & Calin, G. A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0035-x · Cited by 450
Metadata
- Authors
- Liu, T., Zhang, X., Gao, S., Jing, F., Yang, Y., Du, L., Zheng, G., Li, P., Li, C., & Wang, C.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-11-19
- Volume
- 7
- Issue
- 51
- Pages
- 85551-85563
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2549440600
- Cited by
- 302
- References
- 28
- FWCI
- 16.55
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.